- Home
- BELFB vs PHVS Comparison
BELFB vs PHVS Comparison
Compare BELFB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BELFB
- PHVS
- Stock Information
- Founded
- BELFB 1949
- PHVS 2015
- Country
- BELFB United States
- PHVS Switzerland
- Employees
- BELFB N/A
- PHVS N/A
- Industry
- BELFB
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BELFB
- PHVS Health Care
- Exchange
- BELFB Nasdaq
- PHVS Nasdaq
- Market Cap
- BELFB 865.9M
- PHVS 980.9M
- IPO Year
- BELFB N/A
- PHVS 2021
- Fundamental
- Price
- BELFB $99.41
- PHVS $22.99
- Analyst Decision
- BELFB Strong Buy
- PHVS Buy
- Analyst Count
- BELFB 4
- PHVS 6
- Target Price
- BELFB $104.50
- PHVS $37.17
- AVG Volume (30 Days)
- BELFB 166.5K
- PHVS 59.1K
- Earning Date
- BELFB 07-24-2025
- PHVS 08-13-2025
- Dividend Yield
- BELFB 0.28%
- PHVS N/A
- EPS Growth
- BELFB N/A
- PHVS N/A
- EPS
- BELFB 3.42
- PHVS N/A
- Revenue
- BELFB $558,940,000.00
- PHVS N/A
- Revenue This Year
- BELFB $18.21
- PHVS N/A
- Revenue Next Year
- BELFB $7.91
- PHVS N/A
- P/E Ratio
- BELFB $29.48
- PHVS N/A
- Revenue Growth
- BELFB N/A
- PHVS N/A
- 52 Week Low
- BELFB $58.00
- PHVS $11.51
- 52 Week High
- BELFB $103.84
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- BELFB 76.04
- PHVS 67.31
- Support Level
- BELFB $99.04
- PHVS $17.63
- Resistance Level
- BELFB $103.72
- PHVS $26.33
- Average True Range (ATR)
- BELFB 2.64
- PHVS 1.70
- MACD
- BELFB -0.01
- PHVS 0.65
- Stochastic Oscillator
- BELFB 97.69
- PHVS 65.24
About BELFB Bel Fuse Inc. Class B
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.